Newsfile Corp
07 Jan 2026, 19:33 UTC · 42w ago
Verdict
Headline leans bearish. We score CORT −1.00 across two claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
2 claims · scored −1 bearish … +1 bullish
The FDA issued a Complete Response Letter (CRL) for relacorilant as a treatment for hypertension secondary to hypercortisolism, stating it lacked sufficient evidence of effectiveness.
So whatFDA rejection of a primary drug candidate is a severe blow to a pharmaceutical company's pipeline and valuation, as evidenced by the immediate 50% stock price drop.
More negative than 99% of claims this week
Scott+Scott Attorneys at Law LLP is investigating Corcept Therapeutics for potential violations of federal securities laws regarding misleading statements or failure to disclose material information.
Continue reading
5 related stories
More negative than 99% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
More negative than 88% of claims this week
Which stocks this story touches
More negative than 99% of ticker scores this week
The FDA issued a Complete Response Letter rejecting a drug application, leading to a stock price drop of over 50% and a subsequent securities class action investigation.
More negative than 81% of ticker scores this week
The company's directors and officers are being investigated for potential breaches of fiduciary duties.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
3h ago
+140.2%
Price is moving against the score
$85.95 vs $35.78 close before publication (Jan 6) · not market-adjusted
CORT chart →
